MDM2 and colorectal carcinoma: Across a panel of 29 unique CRC cell lines (Additional file 1: Table S6), samples with RAS/BRAFV600E or TP53 mutations had low sensitivity to erlotinib (EGFR inhibitor) and idasanutlin (MDM2/TP53 inhibitor), respectively, while no association between RAS/BRAFV600E mutation status and sensitivity to trametinib (MEK inhibitor) was found (Fig. 5a).